Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/1/2018
SIETES contiene 92186 citas

 
 
 1 a 20 de 167 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]
3. Cita con resumen
Anónimo. Éribuline et liposarcome inopérable réfractaire ou en rechute. Prescrire 2017;37:416-7. [Ref.ID 102000]
4. Cita con resumen
Anónimo. Érythrodysesthésies palmoplantaires des antitumoraux anti-VEGF. Prescrire 2017;37:30-1. [Ref.ID 101368]
5.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
6. Cita con resumen
Anónimo. Bévacizumab et cancer épithélial de l'ovaire résistant aux sels de platine. Prescrire 2015;35:656-7. [Ref.ID 99713]
7. Cita con resumen
Anónimo. Cabozantinib. Prescrire 2015;35:650-3. [Ref.ID 99710]
8.Enlace a cita original Cita con resumen
Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]
9.Tiene citas relacionadas Cita con resumen
Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Messner J, Wilhelm M, Koch P, Lindemann H-W, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, on behalf of the German Hodgkin Study Group the Swiss Group for Clinical Cancer Research the Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015;385:1418-27. [Ref.ID 99035]
10.Tiene citas relacionadas
Casasnovas O, Coiffier B. Hodgkin's lymphoma: better outcomes with fewer drugs?. Lancet 2015;385:1371-3. [Ref.ID 99032]
11. Cita con resumen
Casassus B. Europe urged to take action on drug shortages. Lancet 2015;385:1279-80. [Ref.ID 99016]
12. Cita con resumen
Robak T, Huang H, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F, for the LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015;372:944-53. [Ref.ID 98932]
13. Cita con resumen
Anónimo. Bortézomib en association dans le myélome multiple. Prescrire 2015;35:182-3. [Ref.ID 98926]
14. Cita con resumen
Anónimo. Britain’s NHS cuts funding for costly cancer medicines. DIA Daily 2015:13 de enero. [Ref.ID 98704]
15. Cita con resumen
Anónimo. Lésions de la muqueuse oesophagienne d'origine médicamenteuse. Prescrire 2014;34:905-10. [Ref.ID 98473]
16. Cita con resumen
Anónimo. Atteintes des ongles d'origine médicamenteuse. Prescrire 2014;34:191-4. [Ref.ID 97362]
17.Tiene citas relacionadas
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-26. [Ref.ID 95505]
18.Tiene citas relacionadas
Cheson BD. Therapy for diffuse large B-cell lymphoma: getting personal. Lancet 2013;381:1793-4. [Ref.ID 95497]
19. Cita con resumen
Anónimo. Pazopanib et sarcomes des tissus mous. Prescrire 2013;33:178. [Ref.ID 95025]
20. Cita con resumen
Chen J, Long JB, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomymopathy after adjuvant trastuzumab therapy for breast cancer FREE. J Am Coll Cardiol 2012;60:2504-12. [Ref.ID 94307]
Seleccionar todas
 
 1 a 20 de 167 siguiente >>